Form 4: Zevra Therapeutics Chief Legal Officer Exercises First Tranche of Restricted Stock Units

Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, Inc., has exercised 66,666 restricted stock units, converting them into common stock, with 133,334 units remaining to vest.

Summary

• Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, Inc. (ZVRA), acquired 66,666 shares of common stock on June 21, 2025.
• This acquisition resulted from the exercise and settlement of the first tranche of restricted stock units (RSUs).
• Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Mr. Thompson beneficially owns 66,666 shares of common stock directly.
• An additional 133,334 restricted stock units remain outstanding, which will vest and settle in two equal annual installments thereafter, subject to continued service.

Sentiment

Score: 6

Explanation: A routine insider transaction involving the vesting of restricted stock units is generally neutral to slightly positive, as it reflects standard executive compensation and increases the executive's direct equity ownership, aligning their interests with shareholders. It does not, however, indicate significant new strategic or financial developments.

Positives

• The exercise of restricted stock units by a key executive indicates continued commitment and alignment of interests with shareholders.
• The executive is increasing their direct ownership of the company's common stock.

Future Outlook

The remaining 133,334 restricted stock units held by Rahsaan Thompson will vest and settle in two equal annual installments after June 21, 2025, contingent upon his continued service to the company.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the vesting and conversion of restricted stock units, which is a common component of executive compensation packages across publicly traded companies in various industries, including biotechnology and pharmaceuticals.

Comparison to Industry Standards

• The vesting and conversion of restricted stock units as a form of executive compensation is a standard practice widely adopted across industries, including the biotechnology and pharmaceutical sectors.
• The terms of the RSU vesting, including the contingent right to receive common stock and the multi-tranche vesting schedule, are typical for equity incentive plans designed to align executive interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The vesting and settlement of restricted stock units to an executive (Rahsaan Thompson) constitutes a related party transaction as it involves compensation from the company to a key management personnel.

Stakeholder Impact

• Shareholders: The increase in direct common stock ownership by a key executive may be viewed positively as it further aligns management's financial interests with those of the shareholders.
• Employees: This transaction reflects the company's standard executive compensation practices, which can influence overall employee perception of compensation fairness and structure.

Next Steps

• The remaining two tranches of restricted stock units (133,334 units) are scheduled to vest and settle in equal annual installments after June 21, 2025, subject to the reporting person's continued service.

Key Dates

Recommendation

Keywords

Zevra Therapeutics, ZVRA, Rahsaan Thompson, SEC Form 4, insider transaction, restricted stock units, RSU, common stock, executive compensation, beneficial ownership